bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE - Free Report) in a research note released on Sunday morning. The firm issued a sell rating on the biotechnology company's stock.

Several other research analysts have also recently issued reports on BLUE. JPMorgan Chase & Co. raised shares of bluebird bio from an "underweight" rating to a "neutral" rating in a report on Monday, February 24th. Wells Fargo & Company cut their target price on bluebird bio from $40.00 to $5.00 and set an "equal weight" rating for the company in a research note on Monday, February 24th. Baird R W downgraded bluebird bio from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 21st. Finally, Barclays cut their price objective on bluebird bio from $40.00 to $8.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, bluebird bio presently has a consensus rating of "Hold" and an average target price of $44.60.

bluebird bio Stock Performance

BLUE traded down $0.05 during trading on Friday, hitting $4.10. The stock had a trading volume of 15,529 shares, compared to its average volume of 380,160. The firm has a market capitalization of $40.13 million, a P/E ratio of -0.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60. The company's 50-day moving average price is $4.73 and its 200 day moving average price is $7.21.

Hedge Funds Weigh In On bluebird bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Verition Fund Management LLC acquired a new stake in bluebird bio in the third quarter valued at $42,000. Captrust Financial Advisors boosted its position in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company's stock worth $123,000 after buying an additional 77,293 shares in the last quarter. Barclays PLC grew its stake in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company's stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new position in bluebird bio during the 4th quarter valued at about $175,000. Finally, BNP Paribas Financial Markets raised its position in bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company's stock worth $193,000 after acquiring an additional 355,562 shares during the last quarter. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.